Antibodies specific for CD70 and their uses
US11987634B2 · kind B2 · utility
0Cited by
71References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2022 |
| Grant date | May 21, 2024 |
| Priority date | — |
| Expiry date | Jun 1, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.